CYD-TDV has demonstrated prevention against symptomatic infections, as well as asymptomatic infections. Consequently, it could contribute to reducing viral transmission and thus to indirect protection if the vaccine coverage rates are sufficient. However, since CYD-TDV is now indicated only for people with prior dengue infection, it would be difficult to achieve vaccine coverage rates in a population, at which the herd effect could be identified.